Sorrento Therapeutics, Inc.

Louisiana State University and Agricultural & Mechanical College

City of Hope

Covx Technologies Ireland Limited

Covx Technology Ireland, Ltd.

Yanwen Fu

Gunnar F Kaufmann

James T Patterson

Bin Liu

Gang Chen

Venkata Ramana Doppalapudi

Tong Zhu

Curt William Bradshaw

Joel Desharnais

Dingguo Liu

Abhijit Suresh Bhat

Jing-Yu Lai

Heehyoung Lee

Bryan Douglas Oates

Robert P Hammer

Mark L McLaughlin

Hua Yu

Bryan Edward Jones

Andreas Herrmann

Tod J Miller

Henry Hongjun Ji

Raheleh Toughiri

Gunnar Jörg Floris Kaufmann

Ingale Sampat Lalaso

Provided herein are, inter alia, nucleic acid-peptide conjugates including a non-cell penetrating protein (e.g., an Hdm2 targeting peptide) attached at its C-terminus to a phosphorothioate nucleic acid. Attachment of the phosphorothioate nucleic acid to the non-cell penetrating protein conveys stability to and allows for efficient intracellular delivery of the non-cell penetrating peptide. The nucleic acid-peptide conjugates provided herein including embodiments thereof are useful, inter alia, for the treatment of cancer.

Anti-cancer phosphorothioate-coupled peptide conjugates and methods of using the same

Provided are bispecific antibody compounds having the Formula I: wherein, FAB, FAB, and &#x2014;X&#x2014; are as defined herein. The provided bispecific antibody compounds can be used a modulators of target molecules, including CD3, PSMA, CD19, CXCR5, CD33, PDL1, VEGFR2, cMet, or Ax1, and are useful in the treatment of one or more conditions.

Chemically-locked bispecific antibodies

Provided herein are cell penetrating compounds having the Formula I: where, generally, each T is a thiol reactive group (e.g., a phosphorothioate), each L is a linker (e.g., a linear alkyl), and Y is a biologic (e.g., an antibody). Also provided are pharmaceutical compositions including the cell penetrating compounds, and methods of delivering the compound into a cell.

Cell internalizing compounds

Provided are bispecific conjugates having the general formula: pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and their use in the treatment of cancer.

Disulfide bridging conjugates

Provided are compounds having the Formula I or II: and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and their use in the treatment of cancers.

Cell penetrating peptide inhibitors of p53-MDM2 interaction

There is disclosed a process for forming chemically-locked bispecific or heterodimer antibodies, preferably in the IgG class, in high specificity and with high homogeneity. More specifically, there is disclosed a chemically-locked bispecific IgG class antibody having a linkage region joined together with bio-orthogonal click chemistry.

Provided are compounds having the Formula I: pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and their use in the intracellular delivery of antibodies.

Intracellular delivery compounds

Provided are bispecific antibody compounds having the Formula I: wherein, FAB, FAB, and &#x2014;X&#x2014; are as defined herein. The provided bispecific antibody compounds can be used a modulators of target molecules, including CD3, PSMA, CD19, CXCR5, CD33, PDL1, VEGFR2, cMet, or Axl, and are useful in the treatment of one or more conditions.

The present invention provides various uses of VEGF binding peptides, including methods to treat disorders associated with abnormal angiogenesis. In addition, the invention provides VEGF peptides conjugated to antibodies alone and in conjunction with other anti-angiogenic molecules.

Anti-angiogenic compounds

The present invention provides VEGF binding peptides. In addition, the invention provides VEGF peptides conjugated to antibodies alone and in conjunction with other anti-angiogenic molecules. Various uses of the peptides and compounds are provided, including methods to treat disorders associated with abnormal angiogenesis.

Novel peptides are disclosed that may be used as inhibitors of amyloidogenesis, as suppressors of amyloid toxicity, and as therapeutic agents for amyloid-associated diseases such as Alzheimer's disease, Parkinson's Disease, Creutzfeldt-Jakob Disease, Huntington's Disease, and Type II Diabetes. These new &#x3b2;-strand mimics (&#x3b2;-sheet 'blockers'), containing C-disubstituted amino acids, specifically interact with and block the development of the &#x3b2;-sheet structure of the developing fibrils of amyloid diseases, such as Alzheimer's disease amyloid &#x3b2;-peptide (A&#x3b2;). We have discovered that oligomerization of &#x3b2;-sheet structures, including those implicated in amyloid-associated diseases, may be inhibited or even reversed by the presence of extended peptide structures that have only one edge available for hydrogen bonding. Without a second edge that is also available for hydrogen bonding, the extension of a developing &#x3b2;-sheet is blocked by binding to the novel peptides.

Growing community of inventors

San Diego, CA, United States of America

Yanwen Fu